Editas Medicine, Inc. (EDIT)
Market Cap | 373.36M |
Revenue (ttm) | 69.41M |
Net Income (ttm) | -166.13M |
Shares Out | 82.24M |
EPS (ttm) | -2.08 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,542,508 |
Open | 4.610 |
Previous Close | 4.610 |
Day's Range | 4.450 - 4.630 |
52-Week Range | 4.450 - 11.690 |
Beta | 2.05 |
Analysts | Buy |
Price Target | 12.90 (+184.14%) |
Earnings Date | Jul 31, 2024 |
About EDIT
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumor... [Read more]
Financial Performance
In 2023, EDIT's revenue was $78.12 million, an increase of 296.32% compared to the previous year's $19.71 million. Losses were -$153.22 million, -30.49% less than in 2022.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for EDIT stock is "Buy." The 12-month stock price forecast is $12.9, which is an increase of 184.14% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/t/y/press1-2479212.jpg)
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the RUBY trial are free of vaso-occlusive events post- renizgamglogene autogedtemcel (reni-cel) infusion
![](https://cdn.snapi.dev/images/v1/m/e/press19-2479209.jpg)
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post- renizgamglogene autogedtemcel (reni-cel) infusion
![](https://cdn.snapi.dev/images/v1/n/p/conf8-2429641.jpg)
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and ...
![](https://cdn.snapi.dev/images/v1/0/y/press16-2423564.jpg)
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Research includes the first-ever application of AsCas12a in vivo, optimized LNP delivery, and gene editing RNA guide modifications
![](https://cdn.snapi.dev/images/v1/r/a/press4-2417557.jpg)
Editas Medicine Announces First Quarter 2024 Results and Business Updates
Completed adult cohort enrollment and enrolled multiple patients in the adolescent cohort of the Phase 1/2/3 RUBY clinical trial of reni-cel for severe sickle cell disease
![](https://cdn.snapi.dev/images/v1/n/1/conf18-2405477.jpg)
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wedne...
![](https://cdn.snapi.dev/images/v1/m/d/press18-2402508.jpg)
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases Two-year extension for research and development of alpha-beta T cell ...
![](https://cdn.snapi.dev/images/v1/7/q/conf20-2384210.jpg)
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentati...
![](https://cdn.snapi.dev/images/v1/r/q/press8-2297999.jpg)
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
Company aligned with FDA that RUBY is a single Phase 1/2/3 trial On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel in mid-2024 and additional updates b...
![](https://cdn.snapi.dev/images/v1/d/s/conf17-2285497.jpg)
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on We...
![](https://cdn.snapi.dev/images/v1/d/h/conf7-2253040.jpg)
Editas Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that management will participate in the following upc...
![](https://cdn.snapi.dev/images/v1/z/s/press12-2220115.jpg)
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial adolescent cohort, establish in vivo preclinical proof-of-concept fo...
![](https://cdn.snapi.dev/images/v1/e/y/conf12-2214328.jpg)
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the Company's President and CEO Gilmore O'Neill,...
![](https://cdn.snapi.dev/images/v1/w/q/press17-2194563.jpg)
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for CASGEVY™ (exagamglogene autotemcel) Agreement extends Editas Medicine's cash runway into 2026 CAMBRIDGE, Mass., Dec. 13, 2023 (GLO...
![](https://cdn.snapi.dev/images/v1/n/a/press2-2191514.jpg)
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
All RUBY patients with ≥5 months follow-up have achieved a normal hemoglobin level and a fetal hemoglobin level of >40%
![](https://cdn.snapi.dev/images/v1/e/1/press15-2138590.jpg)
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
Company to provide a clinical update on the EDIT-301 RUBY trial for SCD and EdiTHAL trial for TDT in December at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored webi...
![](https://cdn.snapi.dev/images/v1/g/q/conf10-2136248.jpg)
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m. ET Dr. Rabi Hanna from Cleveland Clinic Children's to present EDIT-301 clinical data at ASH on Monday, ...
![](https://cdn.snapi.dev/images/v1/m/b/conf17-2125302.jpg)
Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
CAMBRIDGE, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Fr...
![](https://cdn.snapi.dev/images/v1/y/v/press8-2104322.jpg)
Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease
CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) gran...
![](https://cdn.snapi.dev/images/v1/o/r/press8-2077035.jpg)
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company's ne...
![](https://cdn.snapi.dev/images/v1/s/d/press1-2076217.jpg)
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company's f...
![](https://cdn.snapi.dev/images/v1/7/g/press15-2043009.jpg)
Editas Medicine Announces Upcoming Investor Events
CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that management will participate in the following upc...
![](https://cdn.snapi.dev/images/v1/d/3/press7-2000955.jpg)
Editas Medicine Announces Second Quarter 2023 Results and Business Updates
On track to dose 20 total patients in the EDIT-301 RUBY trial for SCD and provide a clinical update by year-end Commenced parallel patient dosing in the EDIT-301 EDITHAL trial for TDT and on track to ...
![](https://cdn.snapi.dev/images/v1/5/5/press14-1991954.jpg)
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas' Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
CAMBRIDGE, Mass., and DEVENS, Mass.
![](https://cdn.snapi.dev/images/v1/o/t/conf3-1988453.jpg)
Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
CAMBRIDGE, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on We...